Comparable stake leader
Patrick J. Heron
SEC ownership of HilleVax, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001888012.
Disclosed value leader
Patrick J. Heron
Comparable rows
0/10
Latest evidence
17 Sep 2025
- Parsed ownership sources
-
3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Patrick J. Heron
Ranking: Comparable ownership first, then disclosed value
- Latest parsed ownership date
-
17 Sep 2025
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001888012
- Issuer location
- Boston, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of HilleVax, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Patrick J. Heron
Disclosed value leader
Patrick J. Heron
Comparable rows
0/10
Latest evidence
17 Sep 2025
3/4/5
Highest disclosed value: $16,249,818
10 rows are not safely comparable across share classes.
Showing 1-8 of 10 holder rows.
Quick read
Patrick J. Heron has the largest disclosed position value at $16.25M.
0 of 10 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Patrick J. Heron's linked filing trail.
Disclosed position value
Top 4
Patrick J. Heron
$16.25M
David A. Socks
$11.92M
Astrid Borkowski
$3.21M
Sean McLoughlin
$21.2K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-8 of 10 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Patrick J. Heron |
3/4/5
Director
|
—
mixed-class rows
|
$16,249,818
8,575,036 shares
mixed-class rows
|
— | 23 Jun 2025 |
| David A. Socks |
3/4/5
CFO & Chief Business Officer
|
—
class O/S missing
|
$11,920,353
769,055 shares
|
— | 28 Apr 2022 |
| Astrid Borkowski |
3/4/5
Chief Medical Officer
|
—
mixed-class rows
|
$3,208,660
284,744 shares
mixed-class rows
|
— | 08 Feb 2024 |
| Sean McLoughlin |
3/4/5
Chief Operating Officer
|
—
mixed-class rows
|
$21,225
251,250 shares
mixed-class rows
|
— | 28 Mar 2024 |
| Susan Michele Silbermann |
3/4/5
Director
|
—
class O/S missing
|
—
25,000 shares
|
— | 19 Aug 2022 |
| Jaime Sepulveda |
3/4/5
Director
|
—
class O/S missing
|
—
22,500 shares
|
— | 17 Sep 2025 |
| Jeryl L. Hilleman |
3/4/5
Director
|
—
class O/S missing
|
—
22,500 shares
|
— | 17 Sep 2025 |
| Julie L. Gerberding |
3/4/5
Director
|
—
class O/S missing
|
—
22,500 shares
|
— | 17 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 07 Jul 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-16 of 16 reporting-owner rows connected to HilleVax, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
16
Largest Forms 3/4/5 holder
Patrick J. Heron
Net 12M change
$0
Latest report
17 Sep 2025
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Patrick J. Heron | Director | $16,249,818 | Mixed | 23 Jun 2025 | ||
| David A. Socks | CFO & Chief Business Officer | $11,920,353 | Mixed | 28 Apr 2022 | ||
| Astrid Borkowski | Chief Medical Officer | $3,208,660 | Mixed | 08 Feb 2024 | ||
| Sean McLoughlin | Chief Operating Officer | $21,225 | Filing P/S | 28 Mar 2024 | ||
| TAKEDA PHARMACEUTICAL CO LTD | 10%+ Owner | $0 | Mixed | 17 Sep 2025 | ||
| Frazier Life Sciences X, L.P. | 10%+ Owner | $0 | Mixed | 17 Sep 2025 | ||
| Julie L. Gerberding | Director | $0 | Mixed | 17 Sep 2025 | ||
| Aditya Kohli | Director | $0 | Mixed | 17 Sep 2025 | ||
| Shane Maltbie | Chief Financial Officer | $0 | Mixed | 17 Sep 2025 | ||
| Gary Dubin | Director | $0 | Mixed | 17 Sep 2025 | ||
| Jeryl L. Hilleman | Director | $0 | Mixed | 17 Sep 2025 | ||
| Robert Hershberg | President and CEO, Director | $0 | Mixed | 17 Sep 2025 | ||
| Shelley Chu | Director | $0 | Mixed | 17 Sep 2025 | ||
| Jaime Sepulveda | Director | $0 | Mixed | 17 Sep 2025 | ||
| Nanette Cocero | Director | $0 | Mixed | 17 Sep 2025 | ||
| Susan Michele Silbermann | Director | Mixed | 19 Aug 2022 |
Recent insider transactions for HilleVax, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharmaceutical Co Ltd | HLVX | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -6,724,000 | 0 | 17 Sep 2025 | See Explanation of Responses | ||
| Frazier Life Sciences X, L.P. | HLVX | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -17,199 | 0 | 17 Sep 2025 | By Patrick J. Heron | ||
| Frazier Life Sciences X, L.P. | HLVX | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -8,535,337 | 0 | 17 Sep 2025 | By Frazier Life Sciences X, L.P. | ||
| Robert Hershberg | HLVX | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -1,101,498 | 0 | 17 Sep 2025 | Direct | ||
| Nanette Cocero | HLVX | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -17,199 | 0 | 17 Sep 2025 | Direct | ||
| Jeryl L. Hilleman | HLVX | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -59,224 | 0 | 17 Sep 2025 | Direct | ||
| Shelley Chu | HLVX | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -17,199 | 0 | 17 Sep 2025 | Direct | ||
| Gary Dubin | HLVX | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -17,199 | 0 | 17 Sep 2025 | Direct | ||
| Aditya Kohli | HLVX | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -698,171 | 0 | 17 Sep 2025 | Direct | ||
| Julie L. Gerberding | HLVX | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -59,224 | 0 | 17 Sep 2025 | Direct | ||
| Jaime Sepulveda | HLVX | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -59,224 | 0 | 17 Sep 2025 | Direct | ||
| Shane Maltbie | HLVX | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -83,738 | 0 | 17 Sep 2025 | Direct |
* marks a reported price that did not pass the local price check.